PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30539387-10 2019 Similarly, P38/MAPK activity inhibitor, SB203580, also decreased the expressions of p-P38 and MCP-1. SB 203580 40-48 C-C motif chemokine ligand 2 Homo sapiens 94-99 27122781-12 2014 A selective p38 pathway inhibitor SB203580 could also suppress LPS-induced MCP-1 production. SB 203580 34-42 C-C motif chemokine ligand 2 Homo sapiens 75-80 29864522-6 2018 CCL2 increased the phosphorylation levels of PKCalpha (Thr638), P38MAPK (Thr180/Tyr182) and HSP27 (S78/S82) in human platelets, which were abrogated by PKCalpha inhibitor (RO 318220) or P38MAPK inhibitor (SB 203580). SB 203580 205-214 C-C motif chemokine ligand 2 Homo sapiens 0-4 25715004-7 2015 The latanoprost-induced release of IL-6, IL-8, and MCP-1 was attenuated by inhibitors of MAPK (PD98059, SB203580, or JNK inhibitor II) or NF-kappaB (IkappaB kinase 2 inhibitor) signaling pathways. SB 203580 104-112 C-C motif chemokine ligand 2 Homo sapiens 51-56 25581570-12 2015 Furthermore, AGE- or MGO-induced increased expression of VEGF and MCP-1 was significantly reduced in the presence of NAC or SB203580. SB 203580 124-132 C-C motif chemokine ligand 2 Homo sapiens 66-71 30073566-6 2018 Inhibitors of NF-kappaB, ERK, and JNK (BAY117082, PD98059, and SP600125) significantly suppressed the expression of CXCL1 and CCL2 that were induced by LPS for 3 h. However, the p38 inhibitor, SB203580, had no obvious effect on expression levels of CXCL1 and CCL2. SB 203580 193-201 C-C motif chemokine ligand 2 Homo sapiens 126-130 23670941-7 2013 In contrast, increased MCP-1 release was suppressed with JNK inhibitor SP600125 and p38 MAPK inhibitor SB203580 (P < 0.01). SB 203580 103-111 C-C motif chemokine ligand 2 Homo sapiens 23-28 25033895-6 2014 Furthermore, MCP-1-induced secretion of MMP-9 was inhibited by U0126 (inhibitor of the ERK 1/2 pathway) and SB203580 (inhibitor of the p38 MAPK pathway), but not SP600125 (inhibitor of the JNK1/2 pathway). SB 203580 108-116 C-C motif chemokine ligand 2 Homo sapiens 13-18 19201463-5 2009 TNF-mediated stimulation of CCL2 secretion was completely inhibited by incubating the trophoblast cells with the p38-MAPK inhibitor SB203580, whereas CCL5 secretion was inhibited by treating the trophoblast cells with inhibitors specific for JNK (SP600125) and ERK kinase (U0126). SB 203580 132-140 C-C motif chemokine ligand 2 Homo sapiens 28-32 23185512-4 2012 CCL2-mediated VCAM-1 expression was attenuated by CCR2 inhibitor (RS102895), PKCdelta inhibitor (rottlerin), p38MAPK inhibitor (SB203580), and AP-1 inhibitors (curcumin and tanshinone IIA). SB 203580 128-136 C-C motif chemokine ligand 2 Homo sapiens 0-4 20177146-3 2010 Inhibition of p38 MAPK and JNK by their specific inhibitors (SB203580 and SP600125), or inhibition by a dominant negative mutant of p38 MAPK dramatically decreased SAA-induced CCL2 production. SB 203580 61-69 C-C motif chemokine ligand 2 Homo sapiens 176-180 16339163-11 2006 The secretions of CCL2/MCP-1 and CXCL2/MIP-2 stimulated by LMPS were significantly reduced by incubating PTECs with SB203580, an inhibitor of p38 MAPK. SB 203580 116-124 C-C motif chemokine ligand 2 Homo sapiens 18-22 18656701-7 2008 Selective inhibitors of p38 MAPK (SB203580), JNK (SP600125) and ERK (PD98059) could suppress TNF-alpha-induced CCL2 and ICAM-1 expression, while only p38 MAPK and ERK inhibitors could suppress TNF-alpha-induced VCAM-1 expression. SB 203580 34-42 C-C motif chemokine ligand 2 Homo sapiens 111-115 17460254-9 2007 The MMC-related IL-8 and MCP-1 expression was inhibited by both a p38 inhibitor (SB203580) and an ERK inhibitor (PD98059). SB 203580 81-89 C-C motif chemokine ligand 2 Homo sapiens 25-30 17627770-9 2007 Selective inhibitors of p38 MAPK (SB203580), ERK (PD98059), and JNK (SP600125) could differentially inhibit the production of EGF, VEGF and CCL2, thereby suggesting a role for MAPKs in IL-31 functions. SB 203580 34-42 C-C motif chemokine ligand 2 Homo sapiens 140-144 17641061-7 2007 Although IFN-gamma failed to protect neutrophils from cell death at a higher dose of LPS, the p38 MAPK inhibitor SB203580 dramatically increased MCP-1 release and neutrophil survival at this LPS concentration. SB 203580 113-121 C-C motif chemokine ligand 2 Homo sapiens 145-150 16339163-11 2006 The secretions of CCL2/MCP-1 and CXCL2/MIP-2 stimulated by LMPS were significantly reduced by incubating PTECs with SB203580, an inhibitor of p38 MAPK. SB 203580 116-124 C-C motif chemokine ligand 2 Homo sapiens 23-28 15606618-6 2005 IkappaB-alpha phosphorylation inhibitor, BAY 11-7082, and p38 MAPK inhibitor, SB 203580 could decrease the release of IL-8, IP-10 and MCP-1 in the coculture. SB 203580 78-87 C-C motif chemokine ligand 2 Homo sapiens 134-139 16143069-5 2005 The expression of MCP-1 was inhibited by SB203580. SB 203580 41-49 C-C motif chemokine ligand 2 Homo sapiens 18-23 15016614-6 2004 SB203580 and SP600125 dose-dependently inhibited CCL2 secretion and gene expression induced by IL-1 or TNF. SB 203580 0-8 C-C motif chemokine ligand 2 Homo sapiens 49-53 11053056-6 2000 Furthermore, treatment with either PD098059, SB203580, or the JNK-AP-1 inhibitor curcumin diminished the expression of MCP-1 and stromelysin. SB 203580 45-53 C-C motif chemokine ligand 2 Homo sapiens 119-124 12899782-11 2003 Antioxidant or SB 203580, a specific inhibitor of p38, could block the over-expression of MCP-1. SB 203580 15-24 C-C motif chemokine ligand 2 Homo sapiens 90-95 12743010-6 2003 Inhibition of p38 (with SB 203580), ERK 44/42 (with UO126 or PD 98059), or COX-2 (with NS398) each significantly suppressed uric acid-induced MCP-1 expression at 24 hours, implicating these pathways in the response to uric acid. SB 203580 24-33 C-C motif chemokine ligand 2 Homo sapiens 142-147 12732205-7 2003 SB203580 or FR167653, p38 MAPK specific inhibitors, completely suppressed MCP-1 expression. SB 203580 0-8 C-C motif chemokine ligand 2 Homo sapiens 74-79 12697421-5 2003 The induced IL-8 and MCP-1 proteins were almost completely supporessed by U0126, a specific mitogen-activated protein kinase kinase (MEK) inhibitor, or by SB203580, a selective p38 inhibitor. SB 203580 155-163 C-C motif chemokine ligand 2 Homo sapiens 21-26 12667212-5 2003 The production of IL-8 and monocyte chemotactic protein 1 (MCP-1) was attenuated by 50% when these cells were preincubated with the p38 MAPK inhibitor, SB 203580. SB 203580 152-161 C-C motif chemokine ligand 2 Homo sapiens 27-57 12667212-5 2003 The production of IL-8 and monocyte chemotactic protein 1 (MCP-1) was attenuated by 50% when these cells were preincubated with the p38 MAPK inhibitor, SB 203580. SB 203580 152-161 C-C motif chemokine ligand 2 Homo sapiens 59-64 12667212-8 2003 Evaluation of IL-8 and MCP-1 RNA messages by reverse transcription-polymerase chain reaction (RT-PCR) revealed that the inhibitory effect of SB 203580 was associated with a reduction in this parameter. SB 203580 141-150 C-C motif chemokine ligand 2 Homo sapiens 23-28 11154209-8 2001 Furthermore, MCP-1-mediated chemotaxis and transendothelial migration were significantly diminished by a high concentration of SB202190, a broad SAPK inhibitor, or by SB203580, a specific inhibitor of SAPK2/p38, and abolished by pertussis toxin treatment. SB 203580 167-175 C-C motif chemokine ligand 2 Homo sapiens 13-18 12854631-5 2003 We also observed a significant decrease in the expression and the release of eotaxin, MCP-1 and MCP-3 in the presence of SB203580, an inhibitor of p38 MAPK (71 +/- 6%, P < 0.05, n = 8 and 39 +/- 10% P < 0.01, n = 10 respectively), curcumin, an inhibitor of JNK kinase (83 +/- 4.9% and 88 +/- 3.4% respectively, P < 0.01, n = 4). SB 203580 121-129 C-C motif chemokine ligand 2 Homo sapiens 86-91 11549724-8 2001 Blocking either the ERK1/ERK2 or the p38 pathway (with PD98059 or SB203580, respectively) significantly inhibited Bz-ATP-induced MCP-1 expression. SB 203580 66-74 C-C motif chemokine ligand 2 Homo sapiens 129-134 11468165-5 2001 Using the selective p38 MAPK inhibitor SB203580, there was a significant decrease in thrombin-induced interleukin-8 (IL-8) and monocyte chemotactic protein-1 (MCP-1) protein production and messenger RNA steady-state levels. SB 203580 39-47 C-C motif chemokine ligand 2 Homo sapiens 127-157 11468165-5 2001 Using the selective p38 MAPK inhibitor SB203580, there was a significant decrease in thrombin-induced interleukin-8 (IL-8) and monocyte chemotactic protein-1 (MCP-1) protein production and messenger RNA steady-state levels. SB 203580 39-47 C-C motif chemokine ligand 2 Homo sapiens 159-164 11468165-6 2001 In addition, SB203580 decreased IL-8 and MCP-1 production induced by the thrombin receptor-1 agonist peptide (TRAP), suggesting functional links between the thrombin G protein-coupled receptor and the p38 MAPK pathway. SB 203580 13-21 C-C motif chemokine ligand 2 Homo sapiens 41-46 11121811-5 2001 Platelet-induced secretion of MCP-1 and monocyte-endothelium adhesion was reduced by the MAP kinase p38-specific inhibitor SB203580, but not by other kinase inhibitors including PD98059, wortmannin, or rapamycin. SB 203580 123-131 C-C motif chemokine ligand 2 Homo sapiens 30-35 11121811-6 2001 In addition, activated platelets induced transcription of a luciferase reporter construct containing a MCP-1 promotor, an effect that could be inhibited by SB203580. SB 203580 156-164 C-C motif chemokine ligand 2 Homo sapiens 103-108